These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8829257)

  • 1. Pregnancy outcome after treatment with the ergot derivative, cabergoline.
    Robert E; Musatti L; Piscitelli G; Ferrari CI
    Reprod Toxicol; 1996; 10(4):333-7. PubMed ID: 8829257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study.
    Colao A; Abs R; Bárcena DG; Chanson P; Paulus W; Kleinberg DL
    Clin Endocrinol (Oxf); 2008 Jan; 68(1):66-71. PubMed ID: 17760883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
    Lebbe M; Hubinont C; Bernard P; Maiter D
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy outcome after cabergoline treatment in early weeks of gestation.
    Ricci E; Parazzini F; Motta T; Ferrari CI; Colao A; Clavenna A; Rocchi F; Gangi E; Paracchi S; Gasperi M; Lavezzari M; Nicolosi AE; Ferrero S; Landi ML; Beck-Peccoz P; Bonati M
    Reprod Toxicol; 2002; 16(6):791-3. PubMed ID: 12401507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
    Rains CP; Bryson HM; Fitton A
    Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiopulmonary complications of ergot-derivative dopamine agonists.
    Rack MJ; Baran AS; Richert AC; Roffwarg HP
    J Clin Psychiatry; 2004 Oct; 65(10):1429-30; author reply 1430. PubMed ID: 15491249
    [No Abstract]   [Full Text] [Related]  

  • 8. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature.
    Stalldecker G; Mallea-Gil MS; Guitelman M; Alfieri A; Ballarino MC; Boero L; Chervin A; Danilowicz K; Diez S; Fainstein-Day P; García-Basavilbaso N; Glerean M; Gollan V; Katz D; Loto MG; Manavela M; Rogozinski AS; Servidio M; Vitale NM
    Pituitary; 2010 Dec; 13(4):345-50. PubMed ID: 20676778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
    De Vecchis R; Esposito C; Ariano C
    Herz; 2013 Dec; 38(8):868-80. PubMed ID: 23743769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics.
    Coronas R; Cobo J; Giménez-Palop O; Ortega E; Márquez M
    Curr Drug Saf; 2012 Apr; 7(2):92-8. PubMed ID: 22873493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation.
    Auriemma RS; Perone Y; Di Sarno A; Grasso LF; Guerra E; Gasperi M; Pivonello R; Colao A
    J Clin Endocrinol Metab; 2013 Jan; 98(1):372-9. PubMed ID: 23162092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
    Webster J
    Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.
    Ciccarelli E; Grottoli S; Razzore P; Gaia D; Bertagna A; Cirillo S; Cammarota T; Camanni M; Camanni F
    J Endocrinol Invest; 1997 Oct; 20(9):547-51. PubMed ID: 9413809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia.
    Löndahl M; Nilsson A; Lindgren H; Katzman P
    Eur J Endocrinol; 2008 Apr; 158(4):583-5. PubMed ID: 18362307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.
    Motta T; de Vincentiis S; Marchini M; Colombo N; D'Alberton A
    Fertil Steril; 1996 Feb; 65(2):440-2. PubMed ID: 8566276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabergoline for hyperprolactinemia.
    Med Lett Drugs Ther; 1997 Jun; 39(1003):58-9. PubMed ID: 9205431
    [No Abstract]   [Full Text] [Related]  

  • 19. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
    Drake WM; Stiles CE; Bevan JS; Karavitaki N; Trainer PJ; Rees DA; Richardson TI; Baldeweg SE; Stojanovic N; Murray RD; Toogood AA; Martin NM; Vaidya B; Han TS; Steeds RP; ; Baldeweg FC; Sheikh UE; Kyriakakis N; Parasuraman SK; Taylor L; Butt N; Anyiam S
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4189-4194. PubMed ID: 27571182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
    Cavallaro R; Cocchi F; Angelone SM; Lattuada E; Smeraldi E
    J Clin Psychiatry; 2004 Feb; 65(2):187-90. PubMed ID: 15003071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.